Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Bateman

Showing results (81-90 of 161) with videos related to

Pageof 17
Sort By:
Trials|April 25, 2008
Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocolLara R Fairall, Max O Bachmann, Merrick F Zwarenstein, et al.
The Journal of Allergy and Clinical Immunology|March 11, 2016
Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trialEckard Hamelmann, Eric D Bateman, Christian Vogelberg, et al.
Respiratory Medicine|September 1, 2016
Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysisRonald Dahl, Michael Engel, Daniel Dusser, et al.
Respiratory Medicine|February 21, 2012
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trialEric D Bateman, Eugene R Bleecker, Jan Lötvall, et al.
Thorax|November 21, 2013
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF aloneEric D Bateman, Paul M O'Byrne, William W Busse, et al.
The European Respiratory Journal|February 25, 2022
Reply to: Cause or consequence?Eric D Bateman, David B Price, Hao-Chien Wang, et al.
The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
Thorax|December 30, 2023
Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthmaIlka Hoof, Klaus Bønnelykke, Thomas Stranzl, et al.
Respiratory Medicine|January 29, 2022
Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthmaEric D Bateman, Asif H Khan, Yingxin Xu, et al.
Pageof 17

Showing results (81-90 of 161) with videos related to

Sort By:
Pageof 17
Trials|April 25, 2008
Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocolLara R Fairall, Max O Bachmann, Merrick F Zwarenstein, et al.
The Journal of Allergy and Clinical Immunology|March 11, 2016
Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trialEckard Hamelmann, Eric D Bateman, Christian Vogelberg, et al.
Respiratory Medicine|September 1, 2016
Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysisRonald Dahl, Michael Engel, Daniel Dusser, et al.
Respiratory Medicine|February 21, 2012
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trialEric D Bateman, Eugene R Bleecker, Jan Lötvall, et al.
Thorax|November 21, 2013
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF aloneEric D Bateman, Paul M O'Byrne, William W Busse, et al.
The European Respiratory Journal|February 25, 2022
Reply to: Cause or consequence?Eric D Bateman, David B Price, Hao-Chien Wang, et al.
The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
Thorax|December 30, 2023
Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthmaIlka Hoof, Klaus Bønnelykke, Thomas Stranzl, et al.
Respiratory Medicine|January 29, 2022
Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthmaEric D Bateman, Asif H Khan, Yingxin Xu, et al.
Pageof 17